NDATOPICALSPRAY
Approved
Feb 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
19
Data completeness
5/8 — Partial
SERNIVO (betamethasone dipropionate) by Sandoz is clinical pharmacology: topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. Approved for psoriasis, atopic dermatitis. First approved in 2016.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications (2)
Worked on SERNIVO at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.